Citations

Citations to this article as recorded by  

• Seizure recurrence after GLP‐1 receptor agonist initiation in adults with epilepsy
  Majd A. AbuAlrob, Abdullah Hussein, Rand Abdellatif, Adham Itbaisha, Khaled Zammar, Boulenouar Mesraoua
  Epilepsia.2026; 67(3): 1246.     CrossRef
• Engineered exosomal delivery of semaglutide activates SIRT1–FOXO3a–miR-124 signaling and protects against cortical neuroinflammation
  Elsayed A. Elmorsy, Sameh Saber, Ahmed Y. Kira, Manal Mohamed Hatem, Mohammed Alorini, Suzan Awad AbdelGhany Morsy, Hamad Alsaykhan, Abdulaziz A. Alsalloom, Nahla B. Mohamed, Norah Suliman Alsoqih, Rabab S. Hamad, Youssef El-Sayed, Nagwa Mahmoud Ramadan,
  Journal of Drug Delivery Science and Technology.2026; 118: 108078.     CrossRef
• Gastrointestinal Adverse Effects of GLP-1 and Dual GLP-1/GIP Receptor Agonists: A Comprehensive Update in Diabetic and Obese Populations
  Nimet Yılmaz, Mehmet Bastemir
  Diabetes, Metabolic Syndrome and Obesity.2026; Volume 19: 1.     CrossRef
• Glucagon-Like Peptide-1 Receptor Agonists and Acute Pancreatitis: Current Evidence and Clinical Implications
  Kwang Hyun Chung, Jaihwan Kim
  The Korean Journal of Pancreas and Biliary Tract.2026; 31(1): 1.     CrossRef
• Single vs. Dual Agonist Pharmacotherapy for Managing Insufficient Weight Loss and Weight Regain Following Metabolic and Bariatric Surgery: A Comparative Review
  Claudia Reytor-González, Martín Campuzano-Donoso, Gerardo Sarno, Martha Montalvan, Raquel Horowitz, Gianluca Rossetti, Vincenzo Pilone, Luigi Barrea, Giovanna Muscogiuri, Luigi Schiavo, Daniel Simancas-Racines
  Nutrients.2026; 18(4): 553.     CrossRef
• Oral Administration of Crocus sativus Tepals Extract Restores High‐Fat Diet‐Induced Gut Dysbiosis and Modulates Intestinal Inflammation and Hepatic Lipid Metabolism
  Biljana Bursać, Miloš Vratarić, Ljupka Gligorovska, Luisa Bellachioma, Ana Teofilović, Danijela Vojnović Milutinović, Camilla Morresi, Elisabetta Damiani, Tiziana Bacchetti, Ana Djordjevic
  BioFactors.2026;[Epub]     CrossRef
• A Rare Case of Semaglutide-Associated Small Bowel Obstruction Complicated by Acute Kidney Injury Requiring Dialysis
  Suhasini Rallabandi, Mansi Sharma, Krishnamraju Kosuru, Rahul Kashyap
  Cureus.2026;[Epub]     CrossRef
• The pancreatic signal of GLP‐1 receptor agonists: A biliary phenomenon rather than direct toxicity
  Andro Koren, Luciana Koren
  British Journal of Clinical Pharmacology.2026;[Epub]     CrossRef
• Anti‐Obesity Pharmacotherapy and Emerging Multimodal Interventions for Obstructive Sleep Apnea
  Anish Preshy, Cornelius J. Fernandez, Mohammad Hamid Nedai, Joseph M. Pappachan
  Chronic Diseases and Translational Medicine.2026;[Epub]     CrossRef
• Practical management of glucagon-like peptide-1 receptor agonists in gastroenterology: a position paper by the Italian Society of Gastroenterology (SIGE)
  Antonio Facciorusso, Edoardo G Giannini, Matteo Tacelli, Alberto Zanetto, Cristiano Spada, Ivo Boskoski, Manuele Furnari, Grazia Pennisi, Gabriele Capurso, Alessandro Vitello, Giovanni Marasco, Giovanni Sarnelli, Luca Frulloni, Marcello Maida
  Digestive and Liver Disease.2026;[Epub]     CrossRef
• Adverse effects of GLP-1 receptor agonists: Clinical Implications, regulatory perspectives, and future directions
  Riad Mohammed Abdelrahman, Taha Hussein Musa, Ismail Adam Arbab, Eltieb Omer Ahmed, Sahar Ibrahim Gasmallah, Mohammed Jalal, Chiamaka Linda Mgbechidinma, Wafaa Ramadan Ahmed
  Obesity Medicine.2026; 61: 100699.     CrossRef
• New generation anti-obesity drugs and bone health in postmenopausal women
  Jana Tomasová Studýnková
  Vnitřní lékařství.2026; 72(2): 104.     CrossRef
• Re-establishing alliances: “Old Friends” confronting obesity, inflammation, and stress-related psychiatric disorders
  Luke W. Desmond, Christopher A. Lowry
  Brain Behavior and Immunity Integrative.2026; 15: 100166.     CrossRef
• A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Limosilactobacillus fermentum K8-Lb1 Postbiotic on Weight Management and Metabolic Health Outcomes
  Ekaterina Papazova, Susanne Mitschke, Christiane Laue, Jürgen Schrezenmeir
  Nutrients.2026; 18(8): 1174.     CrossRef
• Appetite Regulation and Gastric Emptying of Semaglutide in Non-Diabetic Obese Adults: A Systematic Review
  Uchechukwu Bethel Abioke, Isaac Baiden, Obiageri Ihuarulam Okeoma, Victoria Partey-Newman, Temitope Oluwatosin Adewale, Shadrach Oluchi Onyekezini, Ijeoma Linda Okwuowulu
  Epidemiology and Health Data Insights.2026; 2(3): ehdi035.     CrossRef
• Assessment of knowledge, attitude, and practices towards the usage of antidiabetic drugs for weight loss among Lebanese population
  Dima Kreidieh, Rouba Ballout, Rana Abutaima, Samer A. Kharroubi, Fatima A. Saleh
  BMC Public Health.2026;[Epub]     CrossRef
• A Narrative Review of Weight Management Strategies: From Lifestyle Interventions to Emerging Pharmacotherapies
  Iman Saad Ahmed, Sara Luay Tapponi, Hala Malek Manaa, Amina Soltani, Elzahraa Shehata Hussein, Fatemeh Ali Parvaresh, Zahid Hussain, Jasbir Arora (RSS)
  Journal of Obesity.2026;[Epub]     CrossRef
• The case for primary prevention of obesity in the era of GLP-1 therapies
  Søren Holm, Manuel Tena-Sempere, Dimitrios Koutsouris, George V. Dedoussis, Karl-Heinz Wagner, Sara Arranz, Philippe Froguel, Torsten Bohn, Paulo J. Oliveira, Jeroen Lakerveld, Aakruti Kaikini, Achim Kramer, Adam Selamnia, Adina Weinberger, Adrian Jauch,
  The Lancet Regional Health - Europe.2026; : 101679.     CrossRef
• Response to comment on “Efficacy and safety of GLP-1 receptor agonists in the management of obstructive sleep apnea in individuals without diabetes: A systematic review and meta-analysis of randomized, placebo-controlled trials”
  Chia Siang Kow, Dinesh Sangarran Ramachandram, Syed Shahzad Hasan, Kaeshaelya Thiruchelvam
  Sleep Medicine.2025; 134: 106709.     CrossRef
• Emerging Frontiers in GLP-1 Therapeutics: A Comprehensive Evidence Base (2025)
  Shikha Patel, Sarfaraz K. Niazi
  Pharmaceutics.2025; 17(8): 1036.     CrossRef
• GLP-1 Receptor Agonists in Mood Disorders: A Psychiatric Perspective
  Pietro Carmellini, Alessandro Cuomo, Maria Beatrice Rescalli, Andrea Fagiolini
  Life.2025; 15(9): 1422.     CrossRef
• Development of a risk prediction model for gastrointestinal adverse events associated with semaglutide administration in patients with type 2 diabetes mellitus
  Deyong Yue, Xuesheng Hua, Ling Zhu, Jun Wang, Lihua Gu, Zhengxia Yuan, Wenle Jian, Yirong Chen, Guoliang Meng
  Frontiers in Endocrinology.2025;[Epub]     CrossRef
• Bridging Efficacy and Adherence in Glucagon-Like Peptide-1 Receptor Agonist Therapy: The Emerging Role of Oral Agents
  Sherry Yun Wang, Ryan Stofer, Hao Wang, Gregory A. Brent, Lu Shi, Yu Cai, Moom Roosan, Tannaz Moin
  Diabetes & Metabolism Journal.2025; 49(6): 1331.     CrossRef
• Semaglutide from Bench to Bedside: The Experimental Journey Towards a Transformative Therapy for Diabetes, Obesity and Metabolic Liver Disorders
  Ralf Weiskirchen, Amedeo Lonardo
  Medical Sciences.2025; 13(4): 265.     CrossRef
• Nutrient-Stimulated Hormone-Based Therapies: Transforming Obesity Management
  Ki Hoon Kwak, Chang Hee Jung
  Endocrinology and Metabolism.2025; 40(6): 879.     CrossRef
• Research Progress of GLP-1 Receptor Agonists in the Treatment of Alzheimer’s Disease
  琳娜 勾
  Advances in Clinical Medicine.2025; 15(12): 2047.     CrossRef

Citations

Citations to this article as recorded by  

• Trends in nephrology: kidney metabolism as a therapeutic target
  Jessica S Kleer, Markus M Rinschen
  Nephrology Dialysis Transplantation.2026; 41(2): 193.     CrossRef
• Renoprotective effect of dulaglutide in L-NAME-induced hypertensive nephropathy in rats: insight into the roles of PPAR-gamma and VEGF
  Nermeen Bastawy, Aliaa E. M. K. El-Mosallamy, Rabab Ahmed Rasheed, A. S. Sadek, R. T. Khattab, Esraa Ali, Randa A. Zaghloul, Wael B. A. Ghaly, Amy F. Boushra
  Hypertension Research.2026; 49(3): 816.     CrossRef
• Sodium‐glucose cotransporter 2 inhibitor ameliorates thiazolidinedione‐induced fluid retention through vascular leakage reduction in white adipose tissue
  Ji Yoon Kim, Hye‐Min Jang, Hye‐Jin Lee, Ah Hyeon Lee, Dong‐Hoon Kim, Sin Gon Kim, Nam Hoon Kim
  Diabetes, Obesity and Metabolism.2026; 28(3): 1764.     CrossRef
• Age disparities in SGLT2 inhibitor prescription among people with type 2 diabetes: The role of frailty and sex
  Changyuan Yang, Petra Denig, Lynne Chepulis, Ryan G. Paul, Jung‐Im Shin, Ron T. Gansevoort, Priya Vart
  Diabetes, Obesity and Metabolism.2026; 28(3): 2265.     CrossRef
• Diabetic kidney disease: integrating multi-omics insights, artificial intelligence, and novel therapeutics for precision medicine
  Tao Li, Kaili Chen, Yiting Sun, Linqi Zhang
  Frontiers in Genetics.2026;[Epub]     CrossRef
• Nobiletin Ameliorated the Development of Diabetic Kidney Disease via Modulating Ferroptosis and Epithelial–Mesenchymal Transition Involving Gut–Kidney Axis
  Tingting Zhao, Chuyun Zhao, Qian Xiang, Xi Zhang, Kin-Fong Hong, Peiyu Liu, Zhongyan Sun, Yadi Liu, Ruiting Huang, Yiran Li, Hio-Fai Cheong, Yuwei Wu, Yingqiu Mo, Yiduo Xu, Yingxi Zhao, Qiruo Huang, Ying Xie, Youhua Xu
  The American Journal of Chinese Medicine.2026; 54(01): 303.     CrossRef
• Bridging Innovation and Practice in Type 2 Diabetes Mellitus: Novel Antidiabetic Therapies and the Expanding Role of Community Pharmacists
  Marios Spanakis, Agapi Fournaraki, Frantzeska Nimee, Christos Kontogiorgis, Emmanouil K. Symvoulakis
  Pharmaceuticals.2026; 19(2): 271.     CrossRef
• Diabetic kidney disease in northwest Ethiopia: Prevalence and determinants among adults with type 2 diabetes
  Workagegnehu Hailu, Tadesse Asmamaw Dejene, Markeshaw Tiruneh, Meseret Derbew Molla, Eshetie Melese Birru, Shitaye Alemu, Tadesse Awoke, Francesca D'Addio
  PLOS One.2026; 21(2): e0343210.     CrossRef
• The Role of Non-Coding RNAs in the Pathogenesis and Progression of Diabetic Kidney Disease
  Yinfeng Guo, Yonghao Feng, Henglan Wu, Huanqing Gao
  International Journal of Molecular Sciences.2026; 27(5): 2352.     CrossRef
• Association between cardiovascular-kidney-metabolic syndrome stages and risk of all-cause mortality in U.S. adults: a cross-sectional survey based on NHANES
  Yuanze Du, Wenxue Sun, Jiaqi Zhang, Jinfeng Wang, Kai Deng, Xiaowei Qiao, Jie Zhang, Xiaofang Zhang, Yueyuan Li, Xinyu Zhang, Xin Yang, Fangyu Cheng, Zongshuai Wang, Chunping Wang
  BMC Cardiovascular Disorders.2026;[Epub]     CrossRef
• Integrated discovery of SBLR876: a potent RAGE inhibitor mitigating AGE–RAGE–NF-κB-mediated cytotoxicity and inflammation in diabetic kidney disease
  Mesfer Mohammad AL Shahrani, Mohammad Abohassan, Ayed A. Dera, Sivakumar Vijayaraghavalu, Prasanna Rajagopalan
  Biochemical and Biophysical Research Communications.2026; 811: 153540.     CrossRef
• Glucagon-like peptide-1 receptor agonist and lupus nephritis in systemic lupus erythematosus with type 2 diabetes
  Muhammad Hanif, Jai S. Nagarajan, Ryan Murphy, Shiva P. Sah, Shuang Ye, Andras Perl, Cynthia C. Taub
  The American Journal of Medicine.2026;[Epub]     CrossRef
• Impact of a structured nurse-delivered multi component SGLT2 inhibitor initiation and optimization pathway on kidney function and clinical outcomes in type 2 diabetes and chronic kidney disease: a real-world retrospective study
  Liang Huang, Yi Muhui
  BMC Nephrology.2026;[Epub]     CrossRef
• Інгібітори натрій-глюкозного котранспортера 2-го типу в контексті кардіоренально-метаболічної коморбідності. Частина 2: метаболомічні аспекти нефропротекції
  Vira V. Zlatkina, Andriy O. Nesen, Nadiia V. Demikhova
  Ukrainian Journal of Nephrology and Dialysis.2026; (1(89)): 94.     CrossRef
• Special Issue “Molecular Therapeutics for Diabetes and Related Complications”
  Kota V. Ramana
  International Journal of Molecular Sciences.2025; 26(12): 5585.     CrossRef
• Targeting ion channel networks in diabetic kidney disease: from molecular crosstalk to precision therapeutics and clinical innovation
  Wenfeng Wang, Bi Ke, Chen Wang, Xiaojing Xiong, Xiuyuan Feng, Hua Yan
  Frontiers in Medicine.2025;[Epub]     CrossRef
• SGLT2 Inhibitors and GLP-1 Receptor Agonists in Cardiovascular–Kidney–Metabolic Syndrome
  Aryan Gajjar, Arvind Kumar Raju, Amani Gajjar, Mythili Menon, Syed Asfand Yar Shah, Sourbha Dani, Andrew Weinberg
  Biomedicines.2025; 13(8): 1924.     CrossRef
• Comparative analysis on renal and cardiovascular outcomes of antidiabetic treatment in chronic kidney disease patients—A systematic review and network meta‐analysis
  Peter Bramlage, Anjaly Vijayan, Treesa P. Varghese, Deepthy Melepurakkal Sadanandan, Stefanie Lanzinger, Carmen Ferrero Rodriguez
  Diabetes, Obesity and Metabolism.2025; 27(11): 6254.     CrossRef
• Type 2 Diabetes and the Multifaceted Gut-X Axes
  Hezixian Guo, Liyi Pan, Qiuyi Wu, Linhao Wang, Zongjian Huang, Jie Wang, Li Wang, Xiang Fang, Sashuang Dong, Yanhua Zhu, Zhenlin Liao
  Nutrients.2025; 17(16): 2708.     CrossRef
• Nutriomics and artificial intelligence nutrition obesity cohort (NAINOC): a design paper for a prospective cohort for nutrition and obesity research
  Minyoung Lee, Sungha Park, Soo-Hyun Park, Ho-Young Park, Yu Ra Lee, Min-Sun Kim, Miso Nam, Jangho Lee, Hyein Seo, Yong-ho Lee, Chan Joo Lee, Jae-Ho Park, Hye Hyun Yoo, Hyun-Jin Kim, Kyong-Oh Shin, Yoshikazu Uchida, Kyungho Park
  Clinical Hypertension.2025;[Epub]     CrossRef
• Microvascular Outcomes of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Type 2 Diabetes: A Systematic Review of Retinopathy and Nephropathy Evidence
  Atia Arif, Sanu Lama, Bhavna Singla, Shivam Singla, Sunita Kumawat, Anusha Tharwani, Muhammad Usman, Hamna Khalid, Venkata Madusudana Rao Kanukollu, Osatohanmwen Ekomwereren, Shabir Khan
  Cureus.2025;[Epub]     CrossRef
• Integrating UHPLC-QE-MS and Bioinformatics with Experimental Validation Reveals MAPK/FOS-Mediated Podocyte Apoptosis as the Key Mechanism of Alpiniae oxyphyllae and Saposhnikovia divaricata in Treating Diabetic Kidney Disease
  Xian Wang, Lin Zhang, Rongxin Tang, Wenlong Zhang, Yiqiang Xie, Kai Li
  Pharmaceuticals.2025; 18(10): 1449.     CrossRef
• GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity
  Mark E. Cooper, Daniël H. van Raalte
  Journal of Clinical Investigation.2025;[Epub]     CrossRef
• Short-Term Laboratory Outcomes of SGLT2 Inhibitor Use in Type 2 Diabetic Patients: A Retrospective Analysis
  Hamood AlSudais, Turky AlSulaiman, Badi A. Alotaibi, Abdulrahman Alshalani, Abdulaziz M. Almuqrin, Rehab B. Albakr, Jehad A. Aldali
  Journal of Clinical Medicine.2025; 14(22): 7985.     CrossRef
• Chronic cardiorenal syndrome: cardio-renal protective effect of SGLT2i
  Yixin Zhu, Chenxi Lv, Hanqi Yang, Qian Lu, XuChen Wang, Yueqi Zhang, Maojuan Guo, Bo Yang
  Renal Failure.2025;[Epub]     CrossRef
• FGF4-FGFR1 signaling promotes podocyte survival and glomerular function to ameliorate diabetic kidney disease in male mice
  Jie Zhou, Shuxin Wang, Jiaxin Lou, Beibin Pan, Min Zhao, Qian Li, Jing Zhou, Yali Du, Shuodan Ding, Meiling Yu, Jingjing Zhou, Xinwei Chen, Lingwei Jin, Xinyi Wang, Yepeng Hu, Zhe Wang, Xiaokun Li, Chao Zheng, Jian Sun, Zhifeng Huang
  Nature Communications.2025;[Epub]     CrossRef
• Food‐Herb Dual‐Function in Astragali Radix‐Poria‐Rheum: Network Pharmacology and Database Mining for Diabetic Kidney Disease Mechanisms Exploration
  Meizi Wang, Weizhong Li, Qiong Cheng, Jiayu Sun, Cheng Cheng, Nana Wang, Ping Zhou, Min Zha, Yufeng Yang
  Food Science & Nutrition.2025;[Epub]     CrossRef
• Інгібітори натрій-глюкозного котранспортера 2-го типу в контексті кардіоренально-метаболічної коморбідності. Частина 1: основи патофізіології та ключові клінічні дослідження
  Vira V. Zlatkina, Andriy O. Nesen, Nadiia V. Demikhova
  Ukrainian Journal of Nephrology and Dialysis.2025; (4(88)): 88.     CrossRef
• GLP-1 Receptor Agonists and Blood Pressure: A State-of-the-Art Review of Mechanisms, Evidence, and Clinical Implications
  Areesha Moiz, Tetiana Zolotarova, Kristian B Filion, Mark J Eisenberg
  American Journal of Hypertension.2025;[Epub]     CrossRef

Citations

Citations to this article as recorded by  

• Semaglutide beyond weight loss: Mechanistic insights and functional paradoxes from the SEMALEAN study
  Shambo S. Samajdar, Shashank Joshi
  Diabetes, Obesity and Metabolism.2026; 28(1): 779.     CrossRef
• An expert narrative review on the brain-kidney axis in diabetic kidney disease: Mechanisms and therapeutic insights
  Zongrui Zhang, Rangzi Yi, Shihong Xiong, Yushu Zhang, Xuebin Cao, Wenqi Zhen, Yang Yang, Na Gong
  Diabetes Research and Clinical Practice.2026; 233: 113055.     CrossRef
• Impaired Brain Incretin and Gut Hormone Expression in Human Alcohol-Related Brain Damage: Opportunities for Therapeutic Targeting
  Suzanne M. de la Monte, Ming Tong, Rolf I. Carlson, Greg Sutherland
  Biomolecules.2026; 16(1): 99.     CrossRef
• Plasma GLP-1 (Glucagon-like Peptide-1) Depletion Is Correlated with Dysregulation of Adipocytokine in Type 2 Diabetic Patients With or Without Metabolic-Associated Fatty Liver Disease (MAFLD): A Cross-Sectional Study Related to Gender-Sex Disparities
  Houda Zoubiri, Wassila Saiah, Amel Otmane, Hamza Saidi, Mohamed Makrelouf, Samir Ait Abderrhmane, Ali El Mahdi Haddam, Elhadj-Ahmed Koceir
  International Journal of Molecular Sciences.2026; 27(3): 1218.     CrossRef
• The Enterolimbic Axis: Gut-Brain Affective Circuits at the Crossroad of Metabolism, Emotion, and Behavior
  Antonio Gasbarrini, Francesca Sofia Galli, Gianluca Ianiro, Francesca Ponziani, Emanuele Rinninella
  American Journal of Gastroenterology.2026;[Epub]     CrossRef
• Micronutrient Deficiencies in the Era of Second-Generation Incretin-Based Therapies for Obesity
  Andrijana Koceva, Andrej Janež, Tajda Pečko, Mojca Jensterle
  Nutrients.2026; 18(4): 677.     CrossRef
• National Consensus on Semaglutide in Cardiology: From Clinical Evidence to Clinical Translation
  HK Chopra, Ashwani Mehta, CK Ponde, Navin C Nanda, GS Wander, Abraham Oomman, Prafulla Kerkar, SN Routray, GP Ratnaparkhi, Prashant Advani, Rituparna Shinde, Rajeev Agarwal, Ajay Mahajan, Jay Shah, Gaurav Verma, Sanjay Mittal, Dorairaj Prabhakar, D Ramesh
  Journal of The Association of Physicians of India.2026; 74(2): e8.     CrossRef
• Polysaccharides from Acanthopanax senticosus (Rupr. et Maxim.) Harms: Molecular Messengers Linking the Traditional Efficacy of Fortifying the Spleen, Replenishing Qi, and Calming the Spirit to Gut-Immune Axis Regulation
  Bichun Hu, Deyong Zeng, Junli Liu, Weiping Wang, Shuaimin Hu, Weihong Lu
  Journal of Future Foods.2026;[Epub]     CrossRef
• Obestatin: canonical and unexpected functions
  Icia Santos-Zas, Uxia Gurriaran-Rodriguez, Tania Cid-Diaz, Saul Leal-Lopez, Felipe F. Casanueva, Yolanda Pazos-Randulfe, Jesus P. Camiña
  Reviews in Endocrine and Metabolic Disorders.2026;[Epub]     CrossRef
• The efficacy and safety of novel antidiabetic agents in polycystic ovary syndrome: a network meta-analysis
  Junjie Lin, Rongtao Yang, Jiacheng Zhuang, Wenbo Zhang, Qiang Tong, Jiahui Liu, Ye Kang, Yuan Yuan
  Journal of Ovarian Research.2026;[Epub]     CrossRef
• Hypothalamus-liver talks: whispers in the language of metabolism
  Vitor Ferreira, Iara Fernández-González, Jane Jose Vattathara, Amanda Rodríguez-Díaz, Paola Fernández-Sanmartín, Carlos Diéguez
  Reviews in Endocrine and Metabolic Disorders.2026;[Epub]     CrossRef
• Disproportionality Analysis of Tirzepatide vs. Semaglutide and Liraglutide: System Organ Class-Level Post-Marketing Reporting Patterns in EudraVigilance
  Ruxandra Cristina Marin, Cosmin Mihai Vesa, Delia Mirela Tit, Andrei-Flavius Radu, Gabriela S. Bungau
  International Journal of Molecular Sciences.2026; 27(7): 2988.     CrossRef
• Hijacked Brain in Modern Obesity: Cue, Habit, Addiction, Emotion, and Restraint as Targets for Personalized Digital Therapy and Electroceuticals
  Taesung Lee, Seeun Park, Seokhyun Lee, Areum Hwangbo, HanGyeol Bae, Yumin Lee, Hyung Jin Choi
  Journal of Obesity & Metabolic Syndrome.2025; 34(3): 196.     CrossRef
• Long-Term Efficacy Trajectories of GLP-1 Receptor Agonists: A Systematic Review and Network Meta-Analysis
  Zixuan Li, Zhoubo Han, Rong Sun, Xiuping Xuan, Chenghu Huang
  Diabetes, Metabolic Syndrome and Obesity.2025; Volume 18: 3611.     CrossRef
• The LEPR gene: A multifaceted regulator of energy homeostasis, obesity pathogenesis, and metabolic health
  Isar Sharma, Nishutosh, Kritika Bakshi, Ritu Mahajan, Nisha Kapoor
  Human Gene.2025; 46: 201486.     CrossRef
• Glucagon-Like Peptide-1 Receptor Agonists Are Promising for the Treatment of Brain Diseases: an Outlook from the Perspective of Integrative Physiology
  N. V. Gulyaeva
  Journal of Evolutionary Biochemistry and Physiology.2025; 61(5): 1326.     CrossRef
• Beyond Weight Loss: GLP-1 Usage and Appetite Regulation in the Context of Eating Disorders and Psychosocial Processes
  Isabel Krug, An Binh Dang, Jade Portingale, Yakun Li, Ying Qing Won
  Nutrients.2025; 17(23): 3735.     CrossRef
• A personalized, evidence-based approach to obesity therapy using clinical algorithms: semaglutide or tirzepatide
  E. A. Troshina, M. B. Antsiferov, A. S. Ametov, G. R. Galstyan, T. N. Markova, T. I. Romantsova, N. V. Mazurina, O. M. Koteshkova
  Problems of Endocrinology.2025; 71(5): 19.     CrossRef
• Tirzepatide and Obesity: A Narrative Review
  Arya Singh, Rahnuma Ahmad, Kona Chowdhury, Mahendra Narwaria, Mainul Haque
  Advances in Human Biology.2025;[Epub]     CrossRef

Citations

Citations to this article as recorded by  

• Implications of Glucagon-like Peptide-1 Receptor Agonists on Thyroid Function and Thyroid Nodules: A Drug Target Mendelian Randomization and Cohort Study
  Zhijun Zhang, Jingyun Yang, Ling Gao
  Endocrine Practice.2026; 32(1): 60.     CrossRef
• Insulin resistance and metabolic dysfunction in thyroid nodules and differentiated thyroid cancer
  Stefano Iuliano, Maria Mirabelli, Stefania Giuliano, Antonio Brunetti
  Current Opinion in Oncology.2026; 38(1): 1.     CrossRef
• Assessment of thyroid cancer risk associated with glucagon‐like peptide 1 receptor agonist use
  Tina Vilsbøll, Michael Stellfeld, Vanita R. Aroda, Sune Dandanell, Jens‐Peter David, Ceyda T. P. Kristiansen, Søren Rasmussen, Fiona L. Roberts, Laszlo Hegedüs
  Diabetes, Obesity and Metabolism.2026; 28(2): 1499.     CrossRef
• Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists: A State-of-the-Art Narrative Review
  Setor K. Kunutsor, Samuel Seidu
  Drugs.2026; 86(1): 11.     CrossRef
• Glucagon-like Peptide-1 Receptor Agonist Use and Pancreatic Cancer Risk in Patients with Chronic Pancreatitis
  Sarina Ailawadi, Jennifer E. Murphy, Michael H. Storandt, Amit Mahipal
  Cancers.2026; 18(2): 179.     CrossRef
• Mechanisms in diabetes mellitus: Relationships to metabolism and/or neoplasia
  John A. D'Elia, Bijan Roshan, Larry A. Weinrauch
  Journal of Diabetes and its Complications.2026; 40(4): 109289.     CrossRef
• Glucagon-like peptide-1 receptor agonists and the risk of obesity-related cancers: a systematic review and meta-analysis
  Yousef A. Ateiwi, Rahil Mahmood, Hon Jen Wong, Chen Ee Low, Chun En Yau, Ainsley Ryan Yan Bin Lee, Pei Chia Eng, Matilda Lee, Mark Y. Chan, Ching-Hui Sia
  Diabetes Research and Clinical Practice.2026; 234: 113158.     CrossRef
• Practical management of glucagon-like peptide-1 receptor agonists in gastroenterology: a position paper by the Italian Society of Gastroenterology (SIGE)
  Antonio Facciorusso, Edoardo G Giannini, Matteo Tacelli, Alberto Zanetto, Cristiano Spada, Ivo Boskoski, Manuele Furnari, Grazia Pennisi, Gabriele Capurso, Alessandro Vitello, Giovanni Marasco, Giovanni Sarnelli, Luca Frulloni, Marcello Maida
  Digestive and Liver Disease.2026;[Epub]     CrossRef
• GLP‐1 receptor agonists and the risk for cancer: A meta‐analysis of randomized controlled trials
  Giovanni Antonio Silverii, Christian Marinelli, Costanza Bettarini, Gloria Giovanna Del Vescovo, Matteo Monami, Edoardo Mannucci
  Diabetes, Obesity and Metabolism.2025; 27(8): 4454.     CrossRef
• Evaluating Thyroid Cancer Risk in Glucagon-like Peptide-1 Analog Users With Thyroid Nodules
  Sanjana Balachandra, Rohma Syed, Zhixing Song, Julia Kasmirski, Andrea Gillis, Jessica Fazendin, Brenessa Lindeman, Herbert Chen
  Journal of Surgical Research.2025; 312: 104.     CrossRef
• Exploring the Side Effects of GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning
  Jung A Kim, Hye Jin Yoo
  Diabetes & Metabolism Journal.2025; 49(4): 525.     CrossRef
• Association between Cancer and Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes: A Systematic Review of Retrospective Cohort Studies
  Hyun Jin Park, Si Yoon Lee
  Research in Clinical Pharmacy.2025; 3(1): 28.     CrossRef
• GLP-1 Receptor Agonists Initiation and Risk of Acute Pancreatitis and Pancreatic Cancer: A Real-World Comparative Study
  Omar Faour, Moheb Boktor, Hanford Yau, Mustafa Kinaan, Ishak A Mansi
  American Journal of Medicine Open.2025; 14: 100114.     CrossRef
• Semaglutide and weight management in the Arab countries: Focus on the United Arab Emirates
  Sabina Semiz
  Health Sciences Review.2025; 17: 100244.     CrossRef
• GLP-1 receptor agonists and cancer: current clinical evidence and translational opportunities for preclinical research
  Estefania Valencia-Rincón, Rajani Rai, Vishal Chandra, Elizabeth A. Wellberg
  Journal of Clinical Investigation.2025;[Epub]     CrossRef
• GLP-1 Receptor Agonists in Solid Tumour Therapy: Exploring Their Anticancer Potential and Underlying Molecular Pathways
  Daniela Lucente, Stefania Bellino, Anna La Salvia
  Genes.2025; 16(11): 1352.     CrossRef
• Bridging Efficacy and Adherence in Glucagon-Like Peptide-1 Receptor Agonist Therapy: The Emerging Role of Oral Agents
  Sherry Yun Wang, Ryan Stofer, Hao Wang, Gregory A. Brent, Lu Shi, Yu Cai, Moom Roosan, Tannaz Moin
  Diabetes & Metabolism Journal.2025; 49(6): 1331.     CrossRef
• Joint Society Statement From the Society for Endocrinology (SfE), the British Thyroid Association (BTA) and the British Association of Endocrine and Thyroid Surgeons (BAETS) Regarding the Association of GLP‐1 Agonists and Thyroid Cancer
  Emma Watts, Jonathan Wadsley, Neil Sharma, Kristien Boelaert
  Clinical Endocrinology.2025;[Epub]     CrossRef

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) reduce glycosylated hemoglobin (HbA1c, 0.5% to 1.0%), and are associated with moderate weight loss and a relatively low risk of hypoglycemia. There are differences between Asian and non-Asian populations. We reviewed available data on GLP-1RAs, focusing on Korean patients, to better understand their risk/benefit profile and help inform local clinical practice. Control of postprandial hyperglycemia is important in Asians in whom the prevalence of post-challenge hyperglycemia is higher (vs. non-Asians). The weight lowering effects of GLP-1RAs are becoming more salient as the prevalence of overweight and obesity among Korean patients increases. The higher rate of gastrointestinal adverse events amongst Asian patients in clinical trials may be caused by higher drug exposure due to the lower body mass index of the participants (vs. non-Asian studies). Data on the durability of weight loss, clinically important health outcomes, safety and optimal dosing in Korean patients are lacking. Use of GLP-1RAs is appropriate in several patient groups, including patients whose HbA1c is uncontrolled, especially if this is due to postprandial glucose excursions and patients who are overweight or obese due to dietary problems (e.g., appetite control). The potential for gastrointestinal adverse events should be explained to patients at treatment initiation to facilitate the promotion of better compliance.

Citations

Citations to this article as recorded by  

• Safety and Effectiveness of Dulaglutide in the Treatment of Type 2 Diabetes Mellitus: A Korean Real-World Post-Marketing Study
  Jeonghee Han, Woo Je Lee, Kyu Yeon Hur, Jae Hyoung Cho, Byung Wan Lee, Cheol-Young Park
  Diabetes & Metabolism Journal.2024; 48(3): 418.     CrossRef
• Tolerability and Effectiveness of Switching to Dulaglutide in Patients With Type 2 Diabetes Inadequately Controlled With Insulin Therapy
  Youngsook Kim, Ji Hye Huh, Minyoung Lee, Eun Seok Kang, Bong-Soo Cha, Byung-Wan Lee
  Frontiers in Endocrinology.2022;[Epub]     CrossRef
• Antihyperglycemic Agent Therapy for Adult Patients with Type 2 Diabetes Mellitus 2017: A Position Statement of the Korean Diabetes Association
  Seung-Hyun Ko, Kyu-Yeon Hur, Sang Youl Rhee, Nan-Hee Kim, Min Kyong Moon, Seok-O Park, Byung-Wan Lee, Hyun Jin Kim, Kyung Mook Choi, Jin Hwa Kim
  Diabetes & Metabolism Journal.2017; 41(5): 337.     CrossRef
• Antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus 2017: a position statement of the Korean Diabetes Association
  Seung-Hyun Ko, Kyu-Yeon Hur, Sang Youl Rhee, Nan-Hee Kim, Min Kyong Moon, Seok-O Park, Byung-Wan Lee, Hyun Jin Kim, Kyung Mook Choi, Jin Hwa Kim
  The Korean Journal of Internal Medicine.2017; 32(6): 947.     CrossRef